These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 19812153)

  • 1. Identification of hepatitis C virus NS5A inhibitors.
    Lemm JA; O'Boyle D; Liu M; Nower PT; Colonno R; Deshpande MS; Snyder LB; Martin SW; St Laurent DR; Serrano-Wu MH; Romine JL; Meanwell NA; Gao M
    J Virol; 2010 Jan; 84(1):482-91. PubMed ID: 19812153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.
    Lemm JA; Leet JE; O'Boyle DR; Romine JL; Huang XS; Schroeder DR; Alberts J; Cantone JL; Sun JH; Nower PT; Martin SW; Serrano-Wu MH; Meanwell NA; Snyder LB; Gao M
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3795-802. PubMed ID: 21576451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.
    Zhou S; Williford SE; McGivern DR; Burch CL; Hu F; Benzine T; Ingravallo P; Asante-Appiah E; Howe AYM; Swanstrom R; Lemon SM
    Antiviral Res; 2018 Oct; 158():45-51. PubMed ID: 30081054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
    Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.
    Lin HM; Wang JC; Hu HS; Wu PS; Yang CC; Wu CP; Pu SY; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yeh TK; Yueh A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):44-53. PubMed ID: 22006008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.